GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Financial Strength

INVO Bioscience (INVO Bioscience) Financial Strength : 1 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Financial Strength?

INVO Bioscience has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

INVO Bioscience Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

INVO Bioscience did not have earnings to cover the interest expense. INVO Bioscience's debt to revenue ratio for the quarter that ended in Mar. 2024 was 1.01. As of today, INVO Bioscience's Altman Z-Score is -5.78.


Competitive Comparison of INVO Bioscience's Financial Strength

For the Medical Devices subindustry, INVO Bioscience's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Bioscience's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Financial Strength distribution charts can be found below:

* The bar in red indicates where INVO Bioscience's Financial Strength falls into.



INVO Bioscience Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

INVO Bioscience's Interest Expense for the months ended in Mar. 2024 was $-0.18 Mil. Its Operating Income for the months ended in Mar. 2024 was $-0.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.35 Mil.

INVO Bioscience's Interest Coverage for the quarter that ended in Mar. 2024 is

INVO Bioscience did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

INVO Bioscience's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.028 + 4.352) / 6.304
=1.01

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

INVO Bioscience has a Z-score of -5.78, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -5.78 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INVO Bioscience  (NAS:INVO) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

INVO Bioscience has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


INVO Bioscience Financial Strength Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Bioscience (INVO Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880